BR112014030777A2 - método e composição para aliviar sintomas de tumor - Google Patents

método e composição para aliviar sintomas de tumor

Info

Publication number
BR112014030777A2
BR112014030777A2 BR112014030777A BR112014030777A BR112014030777A2 BR 112014030777 A2 BR112014030777 A2 BR 112014030777A2 BR 112014030777 A BR112014030777 A BR 112014030777A BR 112014030777 A BR112014030777 A BR 112014030777A BR 112014030777 A2 BR112014030777 A2 BR 112014030777A2
Authority
BR
Brazil
Prior art keywords
composition
tumor
combretastatin
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
BR112014030777A
Other languages
English (en)
Inventor
j chaplin David
David Davis Peter
Original Assignee
Angiogene Pharm Ltd
Oxigene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiogene Pharm Ltd, Oxigene Inc filed Critical Angiogene Pharm Ltd
Publication of BR112014030777A2 publication Critical patent/BR112014030777A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo patente de invenção: “método e composição para aliviar sintomas de tumor”. esta invenção refere-se a métodos e a composições para tratamento de síndrome de carcinoide e outros sintomas adversos associados a tumores neuroendócrinos de produção de tumor, referidos métodos compreendendo administrar uma quantidade terapeuticamente eficaz de um agente de ruptura vascular, ou de um sal farmaceuticamente aceitável deste, a um indivíduo tendo um tumor neuroendócrino de produção de hormônio. em implementações preferidas, o agente de ruptura vascular é combretastatina a-4 fosfato, combretastatina a-1 difosfato ou um sal farmaceuticamente aceitável destes.
BR112014030777A 2012-06-21 2013-06-21 método e composição para aliviar sintomas de tumor BR112014030777A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261662635P 2012-06-21 2012-06-21
PCT/US2013/047016 WO2013192506A1 (en) 2012-06-21 2013-06-21 Method and composition for alleviating tumor symptoms

Publications (1)

Publication Number Publication Date
BR112014030777A2 true BR112014030777A2 (pt) 2017-06-27

Family

ID=49769418

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014030777A BR112014030777A2 (pt) 2012-06-21 2013-06-21 método e composição para aliviar sintomas de tumor

Country Status (9)

Country Link
US (1) US20150141349A1 (pt)
EP (1) EP2863924A4 (pt)
JP (1) JP2015525243A (pt)
KR (1) KR20150064711A (pt)
CN (1) CN104379150A (pt)
AU (1) AU2013277053A1 (pt)
BR (1) BR112014030777A2 (pt)
CA (1) CA2874897A1 (pt)
WO (1) WO2013192506A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2343982T1 (sl) 2008-09-17 2017-08-31 Chiasma Inc. Farmacevtski sestavki in metode povezane z dostavo
AU2016215350B2 (en) 2015-02-03 2021-11-25 Amryt Endo, Inc. Method of treating diseases
WO2017031157A1 (en) * 2015-08-18 2017-02-23 Mateon Therapeutics, Inc. Use of vdas to enhance immunomodulating therapies against tumors
IL311974A (en) * 2016-01-21 2024-06-01 Amryt Endo Inc Somatostatin receptor ligands such as octreotide for oral administration to treat the disease
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
WO2023164614A1 (en) * 2022-02-25 2023-08-31 Amryt Endo, Inc. Oral octreotide for treatment of disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996237A (en) * 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
US5590656A (en) * 1992-09-15 1997-01-07 The Ohio State University Research Foundation Application of peptide/cell receptor kinetics utilizing radiolabeled somatostatin congeners in the in situ, in vivo detection and differentiation of neoplastic tissue
US20080214509A1 (en) * 2007-03-02 2008-09-04 Robert Kerbel Methods for enhancing the efficacy of vascular disrupting agents
US8551489B2 (en) * 2008-01-03 2013-10-08 Musc Foundation For Research Development Methods for the treatment of cancers
US20090209496A1 (en) * 2008-02-15 2009-08-20 David Chaplin Methods and compositions for enhancing the efficacy of rtk inhibitors
WO2012061086A2 (en) * 2010-10-25 2012-05-10 Niiki Pharma Inc. Method of treating neuroendocrine tumors

Also Published As

Publication number Publication date
CA2874897A1 (en) 2013-12-27
EP2863924A4 (en) 2015-12-30
JP2015525243A (ja) 2015-09-03
EP2863924A1 (en) 2015-04-29
KR20150064711A (ko) 2015-06-11
AU2013277053A1 (en) 2014-12-04
US20150141349A1 (en) 2015-05-21
WO2013192506A1 (en) 2013-12-27
CN104379150A (zh) 2015-02-25

Similar Documents

Publication Publication Date Title
BR112014030777A2 (pt) método e composição para aliviar sintomas de tumor
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
BR112014008731A2 (pt) tratamento de esclerose múltipla com combinação de laquinimode e fingolimode
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
MX366175B (es) Composiciones fosfolipidicas terapeuticas concentradas.
MX2016011975A (es) Metodos para reducir el riesgo cardiovascular.
BR112015001419A2 (pt) composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios
BR112014004845A2 (pt) pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112014031394A2 (pt) composições e métodos para absorção transmucosa
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
BR112015001847A8 (pt) Composições e tratamento para doenças e distúrbios nos olhos
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
WO2016090024A3 (en) Combination therapy for treatment of cancer
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BRPI0922789A2 (pt) peptídeo de ligação de albumina intermediador para reconhecimento de doença
BR112012032076A2 (pt) composição farmacêutica, e, métodos para tratar um paciente que está sofrendo de um distúrbio e de uma doença neurodegenerativa
MX338746B (es) Vitamina d3 y analogos de la misma para tratar alopecia.
BRPI1015539A2 (pt) composições e métodos para tratamento de queimaduras
WO2019126739A8 (en) Pyrvinium pamoate anti-cancer therapies
BR112015000321A2 (pt) formulações de laquinimod sem agente alcalinizante
WO2014160216A3 (en) Dual targeting anticancer agents
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
WO2015035410A8 (en) Cancer therapy

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]